Is photodynamic therapy with curcumin suitable for combating monkeypox?

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Monkeypox (MPX) is a zoonotic viral infection caused by the Monkeypox Virus (MPXV), which may spread person-to-person directly. It is currently being treated with previously intended drugs for smallpox or other diseases caused by the orthopoxvirus, such as tecovirimat, cidofovir, and brincidofovir. The smallpox vaccination is also the treatment for MPX, consisting of Immune Globulin (IG) combined with human plasma. However, this type of vaccine may cause several neurological adverse events such as headache, pain, vertigo, dizziness, and non-serious limb paresthesia. Up to the present, there are no available treatments, Antimicrobial Photodynamic Therapy (aPDT) may be a good choice for specifically targeting the MPXV because it is a non-invasive approach without side effects. The strategy is according to the principle of Photodynamic Therapy (PDT) and its photodynamic action of curcumin for the research process on MPX. Why do we apply PDT with "curcumin" as a Photosensitizer (PS) against MPX, and is this a possible choice?
How to Cite

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.